Today’s drug screening methods use one or two types of data. However, disease biology is not
replicable by simple screening models because diseases are complex and heterogenous. Yet, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the entire history of medicine. In this article, Dr Aaron Daugherty, Vice President of Discovery at Aria Pharmaceuticals, shares evidence of how we might be missing potential breakthrough therapies.
